EGFR and neoplasm: Canertinib (also known as CI-1033) is an irreversible inhibitor of the four members of the epidermal growth factor receptor (EGFR) tyrosine kinases, shown to inhibit tumour cell growth, and to induce cell apoptosis in several cancer models, such as melanoma and BC [27,28].